Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury
Author:
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference50 articles.
1. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system
2. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats
3. Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects
4. Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease
5. Type of PKD1 Mutation Influences Renal Outcome in ADPKD
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-08-01
2. Structural basis of tolvaptan binding to the vasopressin V2 receptor;Acta Pharmacologica Sinica;2024-06-20
3. Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing;Kidney360;2023-07-07
4. Renal ciliopathies: promising drug targets and prospects for clinical trials;Expert Opinion on Therapeutic Targets;2023-05-04
5. Inactivation of Invs/Nphp2 in renal epithelial cells drives infantile nephronophthisis like phenotypes in mouse;eLife;2023-03-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3